Immunotech Laboratories Inc (IMMB): .

Play Episode

6min

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Krakatoa’s antimony-gold find signals major upside

Krakatoa Resources Ltd chairman Colin Locke talked with Proactive about the company’s newly secured Zopkhito Project in Georgia, which he described as a major opportunity for investors. The project contains a JORC resource of 225,000 tonnes of high-grade antimony at 11% for 26,000 tonnes of metal, translating to a back-of-the-envelope valuation of approximately $1.30 billion based on current prices. Additionally, the project includes 7.1 million tonnes grading 3.7g/t gold for 815,000 ounces, estimated to be worth around $2.50 billion. Locke said, “This is touted to be the sixth biggest antimony project in the world.” The mineralisation is close to surface, and the company believes the resource has strong potential for expansion. He also highlighted the project’s additional gold content as another value driver. He attributed the company’s success in securing the project to its CEO and chief technical officer, Mark Major, whose experience in high-altitude exploration was a key factor for the local vendors. The project’s location in Georgia was described as highly investor-friendly, with a 15% corporate tax rate, no native title or land access complications, and strong support for foreign investment. Locke confirmed that a maiden drilling program is scheduled to begin shortly, with Major heading to Georgia next week to prepare. He emphasised the company’s past success with international projects and reassured investors of the team’s experience. In closing, he noted the company's current market capitalisation of just AUD 5 million, suggesting significant upside. 👉 For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future updates. #ProactiveInvestors #KrakatoaResources #ASX #gold #antimony

Proactive - Interviews for investors

BioHarvest Sciences reports record-breaking 2024 revenue and expansion milestones

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to discuss the company’s impressive financial and operational performance for the fourth quarter and full year ended December 31, 2024. The company reported a remarkable 62% increase in fourth-quarter revenues, reaching $7.3 million, while full-year revenue surged by 99% year-over-year to $25.2 million, surpassing prior guidance. A key driver of this growth has been the continued expansion of VINIA®, BioHarvest’s flagship product line. As of February 2025, total VINIA® subscribers exceeded 50,000, contributing to a cumulative revenue milestone of $50 million since launch. Building on this momentum, the company successfully introduced its VINIA SuperFood Tea line, leveraging its "VINIA Inside" strategy following the successful launch of VINIA SuperFood Coffee in December 2023. Beyond its financial success, BioHarvest achieved several strategic milestones in 2024. Sobel highlighted a groundbreaking partnership with Tate & Lyle to develop plant-based sweeteners, further validating BioHarvest’s innovative Botanical Synthesis platform. Additionally, the company expanded its VINIA product portfolio and completed a successful uplisting to the Nasdaq Global Market, strengthening its position for accelerated growth and operational efficiency in 2025. With a strong foundation and continued product innovation, BioHarvest Sciences is poised to drive further market expansion and deliver sustained shareholder value in the coming year. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

FDA approval sees Orthocell’s Remplir enter multi-billion dollar US nerve market

Orthocell Ltd chairman John van der Wielen talked with Proactive about the company receiving FDA clearance for its nerve repair product, Remplir, paving the way for entry into the multi-billion US healthcare market. The approval marks a significant milestone in Orthocell’s international growth strategy and reflects the strength of its regulatory and clinical capabilities. Van der Wielen emphasised the significance of breaking into the US market in a challenging regulatory environment. “Not many people would have thought with the current US turmoil, a company like ours could achieve FDA clearance,” he said. Orthocell has established operations in the US with logistics and distribution already in place. The company is implementing a hybrid sales model using in-house personnel and regional distributors, aiming for rapid initial uptake with an eye on more exclusive arrangements in the future. Remplir’s three-year shelf life and no temperature control requirement make it ideal for streamlined deployment. He also highlighted that Orthocell has already performed over 2,000 procedures in Australia and anticipates the US market to be 20 to 30 times larger, creating a strong revenue opportunity. With $32 million in cash reserves, the company expects to become cash flow positive within two years. 👉 For more interviews and updates, head to Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications. #Orthocell #FDAApproval #Remplir #NerveRepair #MedicalDevices #BiotechNews #USHealthcare #OrthocellRemplir #InvestorUpdate #ProactiveInvestors #SurgicalInnovation #ASX

Followers	0
Posts	1105
Boards Moderated	0
Alias Born	09/02/2020

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

IMMB Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free